Osilodrostat with steroid replacement in people with Cushing syndrome
Looks at how often adrenal insufficiency occurs with osilodrostat plus glucocorticoid replacement in Cushing syndrome.
Key facts
- Who runs it
- University of Michigan
- Where
- Ann Arbor, United StatesSee the site
- Trial code
- Registry title
- A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
- Status
- Recruiting
- People taking part
- 12 people, planned
- Started
- 19 Jul 2024
- Expected to end
- Jan 2028
- Type of study
- Observational
- Treatments tested
- Osilodrostat
- Record updated
- 9 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with endogenous Cushing syndrome, meaning the body itself makes too much cortisol. They will get osilodrostat together with glucocorticoid replacement as part of their usual care.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Endogenous Cushing syndrome, either after surgery or in people who cannot have surgery.
- Earlier treatment
- People must be under consideration to receive osilodrostat as part of their clinical care. People who had other investigational (trial) drugs within 30 days or five half-lives, whichever is longer, cannot join.
Main reasons for not taking part
- Treatment with other investigational drugs within 30 days or five half-lives, whichever is longer
- Past allergic reaction to osilodrostat or similar medicines
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Endogenous Cushing syndrome, either following surgery or not candidates for surgery
- Under consideration to receive osilodrostat as part of their clinical care
- Able to provide informed consent
Who cannot take part
- Treatment with other investigational drugs within 30 days or five half-lives (whichever is longer)
- A history of hypersensitivity to osilodrostat or therapies of a similar chemical class
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University of MichiganAnn Arbor, United StatesContact: Eyad AlsafadiTaking people
About the trial
What the trial wants to find out
The major goal of this study is to determine the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome receiving osilodrostat treatment combined with a replacement of glucocorticoid (block-and-replace approach).
Read full original descriptionShow less
The investigators are also evaluating new biomarker steroids to reflect adequate osilodrostat dosing, the durability and safety, and clinical improvement during treatment.
The group in the trial
- Observational cohort
Participants with Cushing syndrome consented to participate in block-and-replace osilodrostat therapy.
Treatment: Osilodrostat
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
- Plain-language title
- Osilodrostat with steroid replacement in people with Cushing syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06430528, who can take part
- Record updated
- 9 September 2026